Hemophagocytic lymphohistiocytosis
Conditions
Interventions
DXM group:Dexamethasone (DXM): week1-2: 10 mg/m2.d, week 3-4: 5 mg/m2.d, week5-6: 2.5 mg/m2.d, week7: 1.25 mg/m2.d, week8: tapering.
HLH-94 group:DXM: week1-2: 10 mg/m2.d, week 3-4: 5 mg/m2.d, week5-6: 2.5 mg/m2.d, week7: 1.25 mg/m2.d, week8: tapering.
Etoposide (VP16): 150 mg/m2 in the first two weeks, twice a week, 150 mg/m2 in 3
Sponsors
the Children's Hospital of Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1.Age from one day to 18 years old; 2.Newly diagnosed HLH, fulfilling the HLH criteria; 3.To observed the early diagnosis role of cytokines, patients who is suspected to be HLH and fulfill 3 out of 8 criteria can be pre-enrolled; 4.Signed an informed consent form before participating in the study
Exclusion criteria
Exclusion criteria: 1.Treated with steroids or etoposide within 72 hours before diagnosis. 2.Patient has prior HLH therapy. 3.History of severe allergic, anaphylactic, or other hypersensitivity reactions to chemicals. 4.Patients diagnosed with tumor-associated HLH and macropahge activation syndrome were excluded from the stratification treatmet. 5.Other problems which make the patients unable to undergo this clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response;Overall survival;Overall response rate;Event-free survival ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Reactivation rate;Rate of Early Death;Sustained remission; | — |
Countries
China
Contacts
Public ContactYongmin Tang
Children’s Hospital of Zhejiang University School of Medicine
Outcome results
None listed